从2018年4月开始,香港交易所实行新制度,容许未有收益记录的生物科技公司来港上市。香港市场开放予因未有收益而未能符合传统上市要求(即盈利测试或市值及收益测试)的优质企业,由此迈出重要的第一步。在新制度成立的头两年内,共有16家未有收入的生物科技公司上市,一共募集了397亿港元。

阅读原文 >


This communication, which we believe may be of interest to our clients and friends of the firm, is for general information only. It is not a full analysis of the matters presented and should not be relied upon as legal advice. This may be considered attorney advertising in some jurisdictions. Please refer to the firm's privacy notice for further details.